Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2026 to 2040 of 8933 results

  1. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Imbio CT lung texture analysis for identifying interstitial lung disease (MT618) (MIB272)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  8. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  10. Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

    Technology appraisal guidance
    In consultation

  14. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

    Highly specialised technologies guidance
    Topic prioritisation

  15. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 6 March 2026.

    Technology appraisal guidance
    In consultation